Moderna, Inc. (MRNA) · Insider Trading (Form 4) SEC Filing

=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-05-06 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: Moderna, Inc. (MRNA) CIK: 0001682852 --- Reporting Owner --- Name: Rubenstein David M. CIK: 0001543895 Role: Director --- Derivative Transactions --- [Transaction #1] Security: Stock Option (Right to Buy) Date: 2026-05-06 | Code: A (Grant or award) Shares: +9,681 | Price: $0.00 Exercisable: N/A | Expires: 2036-05-06 Shares Owned After: 9,681 | Ownership: D (Direct) Footnotes: [F1] This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. [Transaction #2] Security: Restricted Stock Units Date: 2026-05-06 | Code: A (Grant or award) Shares: +2,092 | Price: $0.00 Shares Owned After: 2,092 | Ownership: D (Direct) Footnotes: [F2] Restricted stock units convert into common stock on a one-for-one basis. [F3] The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. [F3] The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. --- Footnotes (Complete Index) --- F1: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. F2: Restricted stock units convert into common stock on a one-for-one basis. F3: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. --- Signature --- /s/ /s/ James Dillon, As Attorney-in-Fact (2026-05-08)